|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
JPRN |
|
Last refreshed on:
|
17 October 2023 |
|
Main ID: |
JPRN-UMIN000024507 |
|
Date of registration:
|
21/10/2016 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Drug interaction between methotrexate and salazosulfapyridine in Japanese patients with rheumatoid arthritis
|
|
Scientific title:
|
Drug interaction between methotrexate and salazosulfapyridine in Japanese patients with rheumatoid arthritis - Drug interaction between methotrexate and salazosulfapyridine in Japanese patients with rheumatoid arthritis |
|
Date of first enrolment:
|
2011/05/12 |
|
Target sample size:
|
10 |
|
Recruitment status: |
Complete: follow-up complete |
|
URL:
|
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000028200 |
|
Study type:
|
Interventional |
|
Study design:
|
Single arm Non-randomized
|
|
Phase:
|
Not selected
|
|
|
Countries of recruitment
|
|
Japan
| | | | | | | |
|
Contacts
|
|
Name:
|
Morihiro Okada |
|
Address:
|
Ha-15 Oki-machi, Kanazawa 920-8610, Japan
|
|
Telephone:
|
+81-76-252-2200 |
|
Email:
|
okada-knz@umin.ac.jp |
|
Affiliation:
|
Japan Community Healthcare Organization Kanazawa Hospital Department of Pharmacy |
|
|
Name:
|
Morihiro Okada |
|
Address:
|
Ha-15 Oki-machi, Kanazawa 920-8610, Japan
|
|
Telephone:
|
+81-76-252-2200 |
|
Email:
|
okada-knz@umin.ac.jp |
|
Affiliation:
|
Japan Community Healthcare Organization Kanazawa Hospital Department of Pharmacy |
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria:
Exclusion criteria: patients who showed poor compliance
Age minimum:
20years-old
Age maximum:
100years-old
Gender:
Male and Female
|
|
Health Condition(s) or Problem(s) studied
|
|
rheumatoid arthritis
|
|
Intervention(s)
|
|
In these patients, who had received SASP/MTX combination therapy for at least 12 weeks, SASP was discontinued, and the patients received MTX monotherapy for the next 24 weeks.
|
|
Primary Outcome(s)
|
|
change of serum MTX concentration
|
|
Secondary Outcome(s)
|
|
simplified disease activity index (SDAI) and disease activity score-C reactive protein (DAS28-CRP),levels of matrix metalloproteinase-3 (MMP-3),inflammatory cytokines,questionnaire
|
|
Secondary ID(s)
|
|
1228-2
|
|
2012-002
|
|
Source(s) of Monetary Support
|
|
There are no funding sources for this study.
|
|
Ethics review
|
Status: YES
Approval date:
Contact:
|
|
Results
|
|
Results available:
|
Yes |
|
Date Posted:
|
|
|
Date Completed:
|
13/02/2015 |
|
URL:
|
|
|
|